Vitreous seed classification is predictive of response to intravitreal chemotherapy

DEC 19, 2017

Pediatric Ophth/Strabismus


This retrospective study evaluated outcomes of retinoblastoma treated with intravitreal melphalan as salvage for vitreous seeding.

Study design

The retrospective review included 28 eyes of 25 patients who were treated at Children's Hospital Los Angeles over a 5-year period. All patients received systemic intravenous chemotherapy followed by intravitreal melphalan as salvage treatment for persistent or recurrent vitreous seeding.

Outcomes

Overall, intravitreal chemotherapy was very successful at treating all types of vitreous seeds (dust, spheres, cloud). Clouds required the most injections and took more time to regress than dust or spheres. However, spheres were more likely to recur. There was 100% regression of vitreous seeds after intravitreal melphalan, and no eye was treated with radiation or enucleated for seeding.

Of the 28 treated eyes, the overall globe salvage rate was 68%. Nine eyes were eventually enucleated: 6 eyes because of massive recurrences or recurrences near the optic nerve that were not amenable to local therapy; and 3 from development persistent retinal detachment or neovascular glaucoma with very poor visual prognosis.

Limitations

This study excludes patients who received intra-arterial chemotherapy, yet included those who received intravenous chemotherapy. Therefore, the size of the study is very low for a 5-year period. Also, follow-up data was limited to a small cohort, as a third of these eyes were enucleated.

Clinical significance

This study found that the number of injections and required dose of intravitreal melphalan is dependent on the class of retinoblastoma seed, regardless of primary therapy. Anticipating that patients with clouds may require more injections allows for better counseling of families with children who are undergoing intravitreal chemotherapy.

View Abstract Ophthalmology, December 2017

https://www.aao.org/editors-choice/vitreous-seed-classification-is-predictive-of-resp

Comments

Post a Comment

Popular posts from this blog

Week in review: Pay raise, Von’s Vision, gonio-<em>what?</em>

Image
APR 13, 2018 By Anni Griswold Comprehensive Ophthalmology, Cornea/External Disease, Glaucoma, Pediatric Ophth/Strabismus Above: The GonioPEN (Credit: Nanyang Technological University) A weekly roundup of ophthalmic news from around the web. Ophthalmologists earn more than the average physician , and their salaries are on the rise (+3% over the last year, to be precise). Eye docs will earn a mean $375,000 this year—more than the physician average of $299,000, but well below a typical plastic surgeon’s paycheck. See for yourself in Medscape’s 2018 Physician Compensation Report . Medscape A special supplement to USA Today will highlight the work of Von Miller , a 28-year-old linebacker for the Denver Broncos and former Super Bowl MVP. Through his foundation, Von’s Vision, Miller connects thousands of underprivileged children in Denver with affordable, high-quality eye care. His interview will appear in the “Vision Health” campaign during World Glaucoma Week, available in pr...
Read more

Patch with Microneedles Could Replace Eye Injections

Image
Instead of getting eye injections, patients with serious eye diseases may be eligible for a contact lens-type patch. 1 Injections are often recommended for eye diseases such as Wet (advanced) Age-Related Macular Degeneration, macular edema, and glaucoma. The new patch is inserted painlessly like a contact lens. It delivers tiny microneedles containing medication. The microneedles are made from natural materials and dissolve over time, gradually releasing medicine. Patients would be more likely to stick with a regimen that does not involve eye injections. Eye Injections: Stick a Needle in My Eye Patients generally dread eye injections. Injections must be performed in a doctor’s office. Eye injections can be painful, and they are inconvenient. They can introduce infection. And they can damage the eye. Avastin, Eylea, and Lucentis are injectable medications that discourage new blood vessel growth. These anti-VEGF medicines are useful for advanced Macular Degeneration , Diabetic Retino...
Read more

Incidence of eyelid SCC appears to be rising

FEB 12, 2018 Oculoplastics/Orbit This retrospective study examined demographic risk factors for developing eyelid squamous cell carcinoma (SCC). Study design Using data from the National Cancer Registration and Analysis Service, investigators identified all cases of eyelid SCC in England between 2000 and 2014. Outcomes Over the 15-year study period, there were 4,022 patients with newly diagnosed SCC affecting the eyelid. The age-standardized number of reported cases of eyelid SCC rose approximately 2% per year over the study period. The risk for developing an eyelid SCC approximately doubled each decade after age 60. Men were at 1.9-times greater relative risk compared with women. The authors did not find any association between income quintile and risk of SCC. Limitations The cause for the increasing incidence of eyelid SCC was not studied. While age may represent one factor, others such as an increasing rate of patients receiving immunosuppression therapies may als...
Read more